Incyte's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Incyte Corporation (INCY)

Q2 2012 Earnings Call

August 2, 2012 08:30 am ET


Paul Friedman – President & Chief Executive Officer

Patricia Andrews – Executive Vice President & Chief Commercial Officer

Dave Hastings – Executive Vice President & Chief Financial Officer

Rich Levy – Executive Vice President & Chief Drug Development and Medical Officer

Pamela Murphy – Vice President, Investor Relations and Corporate Communications


Matt Roden – UBS

Brian Abrahams – Wells Fargo

Salveen Richter – Canaccord Genuity

Ian Somaiya – Piper Jaffray

Cory Kasimov – JP Morgan

Thomas Wei – Jefferies & Co.

Rachel McMinn – Bank of America

Tom Russo – Robert W. Baird

Lisa Bayko – JMP Securities

Eric Schmidt – Cowen & Company

Christina – Barclays Capital

David Friedman – Morgan Stanley

Boris Peaker – Oppenheimer

David Crump – Morningstar

Mani Mohindru – ThinkEquity



Greetings, ladies and gentlemen, and welcome to the Incyte Corporation’s Q2 2012 Earnings Call. A brief question-and-answer session will follow the formal presentation. (Operator instructions.) As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Pamela Murphy, Vice President Investor Relations and Communications. Thank you Ms. Murphy, you may now begin.

Pamela Murphy

Good morning and welcome to Incyte’s Q2 2012 conference call. On the call today are Paul Friedman, Incyte’s President and Chief Executive Officer; Pat Andrews, Executive Vice President and Chief Commercial Officer; Dave Hastings, Executive Vice President and Chief Financial Officer; and Rich Levy, Executive Vice President and Chief Drug Development and Medical Officer. Pat is traveling outside of the country right now and is therefore not in the room with us. Paul will begin with a brief overview of the quarter, Pat will update you on the product launch of Jakafi, and Dave will describe the Q2 2012 financial results.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)